文献速递肾小球疾病急性肾损伤

癌症免疫治疗相关肾病综合征:2例病例报告

Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases.
PubMed 文献 · Am J Kidney Dis · 2017-06-23

本文报告2例接受免疫检查点抑制剂(抗PD-1抗体帕博利珠单抗和抗CTLA-4抗体伊匹木单抗)治疗后发生肾病综合征的病例,肾活检均提示微小病变型肾病,停药并糖皮质激素治疗后蛋白尿和急性肾损伤改善,其中1例再次挑战伊匹木单抗后肾病综合征复发。提示免疫治疗激活与肾病综合征发生可能存在关联,需监测肾脏不良反应。

要点

  • 免疫检查点抑制剂(PD-1/CTLA-4)治疗后可发生微小病变型肾病综合征。
  • 停药联合糖皮质激素治疗可改善蛋白尿和急性肾损伤。
  • 再次挑战免疫治疗可能导致肾病综合征复发。

核心结论

  • 免疫检查点抑制剂治疗与肾病综合征发生可能存在关联。
  • 鉴于肿瘤免疫治疗日益普及,应监测患者肾脏不良反应。

研究设计与样本

  • 病例报告,共2例接受免疫检查点抑制剂治疗的患者。

主要发现

  • 患者1接受帕博利珠单抗治疗霍奇金淋巴瘤,第二剂后出现肾病综合征和急性肾损伤,活检示弥漫性足突融合符合微小病变型肾病及急性肾小管损伤表现。
  • 患者1停用帕博利珠单抗并糖皮质激素治疗后蛋白尿和急性肾损伤改善。
  • 患者2接受伊匹木单抗治疗黑色素瘤,出现肾病综合征,活检符合微小病变型肾病。
  • 患者2停用伊匹木单抗并糖皮质激素治疗后蛋白尿缓解,再次挑战伊匹木单抗后肾病范围蛋白尿复发。

临床怎么用

  • 对接受免疫检查点抑制剂治疗的患者应监测肾脏不良反应,包括肾病综合征。
  • 发生免疫治疗相关肾病综合征时,可考虑停用免疫治疗并给予糖皮质激素治疗。
  • 再次挑战免疫治疗需警惕肾病综合征复发。

局限性

  • 仅为2例病例报告,无法确立因果关系。
  • 样本量小,结论推广受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oncologic immunotherapies use a patient's immune response to eliminate tumor cells by modulation of immune checkpoints, including programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) proteins. Immune-mediated sequelae, including interstitial nephritis, have been reported; however, glomerular disease appears rare. We describe 2 cases of nephrotic syndrome in patients treated with these agents. Patient 1 received the anti-PD-1 antibody pembrolizumab for Hodgkin lymphoma. Following his second dose, he developed nephrotic syndrome and acute kidney injury. Biopsy showed diffuse foot-process effacement consistent with minimal change disease and findings of acute tubular injury. Pembrolizumab therapy cessation and corticosteroid treatment yielded improvement in proteinuria and acute kidney injury. Patient 2 received the CTLA-4 antibody ipilimumab for melanoma. He developed nephrotic syndrome with biopsy changes consistent with minimal change disease. Ipilimumab therapy was stopped and proteinuria resolved following corticosteroid treatment. Ipilimumab rechallenge caused relapse of nephrotic-range proteinuria. These cases suggest an association between therapeutic immune activation and the development of nephrotic syndrome. Given the increasing prevalence of oncologic immunotherapies, monitoring patients for renal sequelae is warranted.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Kitchlu A, Fingrut W, Avila-Casado C, et al. Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases. Am J Kidney Dis. 2017. PMID: 28648302. doi:10.1053/j.ajkd.2017.04.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。